文献速递胸部肿瘤

NEJ009研究更新分析:吉非替尼单药对比吉非替尼联合化疗治疗EGFR突变非小细胞肺癌

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
PubMed 文献 · J Clin Oncol · 2022-08-12

NEJ009是一项随机开放标签III期研究,比较吉非替尼联合化疗(GCP)与吉非替尼单药一线治疗EGFR突变非小细胞肺癌。更新分析显示GCP组PFS2显著优于吉非替尼组(HR 0.77,95%CI 0.62-0.97,P=0.027),但更新中位OS在两组分别为49.0个月和38.5个月(HR 0.82,95%CI 0.64-1.06,P=0.127),无显著差异。自首次报告以来未发生严重不良事件。

要点

  • GCP组PFS2显著优于吉非替尼组(HR 0.77,95%CI 0.62-0.97,P=0.027)。
  • 更新中位OS吉非替尼组38.5个月 vs GCP组49.0个月,无显著差异(HR 0.82,95%CI 0.64-1.06,P=0.127)。
  • 自首次报告以来两组均未发生严重不良事件。

核心结论

  • 更新分析显示,与吉非替尼单药相比,GCP方案改善了PFS和PFS2,且安全性可接受。
  • GCP作为EGFR突变非小细胞肺癌一线治疗比吉非替尼单药更有效。

研究设计与样本

  • 随机、开放标签、III期NEJ009研究。
  • 患者随机分配至吉非替尼组(吉非替尼250 mg口服,每日一次)或吉非替尼联合卡铂加培美曲塞组(GCP:3周为一周期,共6周期,随后吉非替尼联合培美曲塞维持治疗)。
  • 数据截止日期为2020年5月22日。

主要发现

  • GCP组PFS2显著优于吉非替尼组(HR 0.77,95%CI 0.62-0.97,P=0.027)。
  • 更新中位OS在吉非替尼组为38.5个月(95%CI 31.1-47.1),在GCP组为49.0个月(95%CI 41.8-56.7),两组无显著差异(HR 0.82,95%CI 0.64-1.06,P=0.127)。
  • 自首次报告以来未发生严重不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.In a randomized, open-label, phase III NEJ009 study, gefitinib plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) compared with gefitinib-alone in patients with untreated non-small-cell lung cancer harboring mutations in epidermal growth factor receptor. Herein, we report the updated survival outcome and long-term tolerability. Patients were randomly assigned to gefitinib (gefitinib 250 mg orally, once daily) and gefitinib combined with carboplatin plus pemetrexed (GCP in a 3-week cycle for six cycles followed by concurrent gefitinib and pemetrexed maintenance) groups. At the data cutoff (May 22, 2020), GCP demonstrated significantly better PFS2 (hazard ratio, 0.77; 95% CI, 0.62 to 0.97; P = .027) than gefitinib. However, the updated median OS was 38.5 months (95% CI, 31.1 to 47.1) and 49.0 months (95% CI, 41.8 to 56.7) in the gefitinib and GCP groups, respectively (hazard ratio, 0.82; 95% CI, 0.64 to 1.06; P = .127). The OS in both groups was similar for the overall patient population. No severe adverse events occurred since the first report. This updated analysis revealed that the GCP regimen improved PFS and PFS2 with an acceptable safety profile compared with gefitinib-alone. GCP is more efficient than gefitinib monotherapy as a first-line treatment for non-small-cell lung cancer with epidermal growth factor receptor mutations.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Miyauchi E, Morita S, Nakamura A, et al. Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR. J Clin Oncol. 2022. PMID: 35960896. doi:10.1200/JCO.21.02911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。